Halozyme Therapeutics (NASDAQ:HALO) Downgraded by BidaskClub

BidaskClub downgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a hold rating in a report released on Friday morning, BidAskClub reports.

Other equities analysts have also recently issued reports about the stock. ValuEngine raised shares of Zogenix from a buy rating to a strong-buy rating in a research note on Thursday, June 27th. Zacks Investment Research cut shares of ExlService from a hold rating to a sell rating in a research note on Wednesday, July 10th. Finally, Cantor Fitzgerald started coverage on shares of Veru in a research note on Monday, July 1st. They set an overweight rating and a $6.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $21.00.

Shares of NASDAQ:HALO opened at $16.91 on Friday. Halozyme Therapeutics has a 52 week low of $13.24 and a 52 week high of $18.85. The stock has a market cap of $2.41 billion, a PE ratio of -30.20 and a beta of 1.77. The business has a fifty day simple moving average of $16.23. The company has a quick ratio of 2.72, a current ratio of 2.95 and a debt-to-equity ratio of 0.07.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. The business had revenue of $56.95 million during the quarter, compared to analysts’ expectations of $67.80 million. During the same period last year, the company posted ($0.19) EPS. The business’s revenue was up 84.3% on a year-over-year basis. On average, equities research analysts forecast that Halozyme Therapeutics will post -0.42 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Arete Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter valued at about $3,461,000. Geode Capital Management LLC boosted its position in Halozyme Therapeutics by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 1,520,657 shares of the biopharmaceutical company’s stock valued at $22,247,000 after buying an additional 76,753 shares during the period. 361 Capital LLC boosted its position in Halozyme Therapeutics by 11.0% in the 1st quarter. 361 Capital LLC now owns 177,474 shares of the biopharmaceutical company’s stock valued at $2,857,000 after buying an additional 17,601 shares during the period. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter valued at about $6,519,000. Finally, Private Advisor Group LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter valued at about $226,000. 82.07% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Read More: Do stock splits help investors?

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit